ATLANTA, GA--(MARKET WIRE)--Jul 25, 2008 -- AtheroGenics, Inc. (AGIX - News), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced that it will release its second quarter 2008 financial results on Tuesday, August 5, 2008 before the U.S. financial markets open.

Conference Call and Webcast Information

Company officials will discuss second quarter 2008 financial results via conference call and webcast on Tuesday, August 5, 2008, at 9:00 a.m. EDT. Participants may access the live conference call by dialing 877-407-8031 (domestic) or 201-689-8031 (international). To access the webcast, please visit the AtheroGenics Investor Relations website at www.atherogenics.com. A replay of the conference call will be accessible approximately one hour after the conclusion of the call by dialing 877-660-6853 (domestic) or 201-612-7415 (international), account number 286, conference ID number 292374. A replay of the webcast will be archived on the Company's website until November 6, 2008.

About AtheroGenics

AtheroGenics is focused on the discovery, development and commercialization of novel drugs for the treatment of chronic inflammatory diseases, including diabetes and coronary heart disease (atherosclerosis). The Company's lead product candidate, AGI-1067, is a novel antioxidant and anti-inflammatory agent that is currently being evaluated in a Phase III registration study called ANDES (AGI-1067 as a Novel Anti-Diabetic Agent Evaluation Study) as an oral treatment for Type 2 diabetes. In addition, the Company has other clinical and preclinical anti-inflammatory compounds, including AGI-1096, an oral agent for the prevention of organ transplant rejection. For more information about AtheroGenics, please visit http://www.atherogenics.com.

     CONTACTS:
      
     AtheroGenics, Inc.
     Mark P. Colonnese
     Executive Vice President
     678-336-2511
     Email Contact
      
     Media Inquiries
     Jayme Maniatis / Dana Conti
     Schwartz Communications, Inc.
     781-684-0770
     Email Contact
      
     Investor Inquiries
     Lilian Stern
     Stern Investor Relations, Inc.
     212-362-1200
     Email Contact